SAB Biotherapeutics Inc

NASDAQ:SABS   3:59:51 PM EDT
1.89
-0.01 (-0.53%)
Earnings Announcements

SAB Biotherapeutics Provides Company Update And Reports Full Year 2021 Financial Results

Published: 03/29/2022 21:28 GMT
SAB Biotherapeutics Inc (SABS) - Sab Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results.
Sab Biotherapeutics Inc - Sufficient Cash and Government Funding Anticipated to Operate Through Q3 2023.
Revenue is expected to be $12 Million
Adjusted EPS is expected to be -$0.13

Next Quarter Revenue Guidance is expected to be $12.43 Million
Next Quarter EPS Guidance is expected to be -$0.12

More details on our Analysts Page.